Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma
J Kuruvilla, M Savona, R Baz… - Blood, The Journal …, 2017 - ashpublications.org
Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …
[HTML][HTML] Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma
J Kuruvilla, M Savona, R Baz, PM Mau-Sorensen… - Blood, 2017 - Elsevier
Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma
J Kuruvilla, M Savona, R Baz… - …, 2017 - mdanderson.elsevierpure.com
Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma
J Kuruvilla, M Savona, R Baz… - …, 2017 - ohiostate.elsevierpure.com
Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.
J Kuruvilla, M Savona, R Baz, PM Mau-Sorensen… - Blood, 2017 - europepmc.org
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. -
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma
J Kuruvilla, M Savona, R Baz, PM Mau-Sorensen… - …, 2017 - pubmed.ncbi.nlm.nih.gov
Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma
J Kuruvilla, M Savona, R Baz, PM Mau-Sorensen… - Blood, 2017 - profiles.wustl.edu
Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma
J Kuruvilla, M Savona, R Baz, PM Mau-Sorensen… - Blood, 2017 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Patients with relapsed or refractory (R/R) non-
Hodgkin lymphoma (NHL) have a poor prognosis and limited treatment options. We …
Hodgkin lymphoma (NHL) have a poor prognosis and limited treatment options. We …
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma
J Kuruvilla, M Savona, R Baz, PM Mau-Sorensen… - Blood, 2017 - research.regionh.dk
Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …
